Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event
复制标题
DOI：
10.1016/j.lungcan.2009.10.007
复制
发表时间：
2010-02-01
期刊：
影响因子：
5.3
通讯作者：
Kohno, Shigeru
中科院分区：
文献类型：
--
作者：
Ide, Shotaro;Soda, Hiroshi;Kohno, Shigeru
目前还没有文献报道与索拉非尼相关的间质性肺病病例。然而，最近日本的一项上市后调查显示，在接受索拉非尼治疗的大约2000名日本患者中，有4人发生了间质性肺炎。在这篇文章中，我们描述了一位日本患者，可能是由索拉非尼治疗转移性肾细胞癌引起的严重间质性肺炎。监督未来肺癌临床试验的肿瘤学家应该警惕这样一个事实，即索拉非尼可能会导致严重的间质性肺疾病，尽管这可能取决于种族差异。(C)2009爱思唯尔爱尔兰有限公司。保留所有权利。
There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences. (C) 2009 Elsevier Ireland Ltd. All rights reserved.